The study is an investigator-initiated study and is being conducted in collaboration with Ellex R&D Pty Ltd, the Australian manufacturer of laser systems for eye diseases. The trial has sites overseas and in Sydney, Perth and Melbourne, with a new site in Adelaide planned soon. Participants attend seven visits over 36 months and receive laser treatment every six months. Fifty per cent of participants will be treated with the laser and the other fifty per cent treated with sham laser.
To be involved in the study participants need to have bilateral intermediate drusen (>125µm) with or without pigmentary changes and best corrected visual acuity of 6/12 or better.
Exclusion criteria are any retinal sign suggestive of geographic atrophy (GA) or choroidal neovascularisation (CNV); sub-foveal pigment epithelial detachment greater than 1000µm in diameter in either eye; and ocular disease in either eye, other than AMD, which may significantly compromise assessment of the retina.
For further information contact Kate Brassington: firstname.lastname@example.org or call 03 9929 8360